Navigation Links
Radioimmunotherapy could extend lives of advanced lymphoma patients
Date:6/11/2013

Vancouver, British Columbia A new patient protocol for aggressive and recurrent lymphoma that combines intensive chemotherapy and radioimmunotherapy (RIT) may become the most powerful cancer-killing therapy available, with the hope that patients' lymphoma can be eradicated as they prepare for bone marrow transplant, say researchers at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. In a study presented at the meeting, survival rates without recurrence improved with the addition of RIT, with some having a 100 percent chance of survival over two years.

"This is a unique randomized study aimed at evaluating a novel treatment approach in patients who have relapsed and aggressive lymphoma with a grave prognosis," said S. Tzila Zwas, MD, professor of nuclear medicine at Sackler School of Medicine, Tel-Aviv University, and Sheba Medical Center in Ramat Gan, Israel. "Currently the best choice for these patients is bone marrow transplantation preceded by high dose chemotherapy with a preparation called BEAM to enhance their response to this engraftment treatment. Here we are studying the effectiveness of a new treatment adding targeted RIT to this standard in order to improve patients' survival."

BEAM is a high-dose chemotherapynamed after its drug constituents carmustine (BiCNU), etoposide, cytarabine (arabinoside) and melphalandeveloped to treat invasive bone marrow cancer. This research compares standard BEAM with BEAM and the addition of RIT with Y-90 ibritumomab tiuxetan (Zevalin), a radionuclide that emits a cancer-killing dose of radiation. This allows doctors to monitor how patients respond to therapy. The new treatment combination is known as Z-BEAM.

In this two-part multicenter prospective study, a total of 43 patients with remaining or relapsed lymphoma were randomized and received one of the two possible treatments prior to bone marrow transplant. Patients who underwent BEAM chemotherapy alone had a 43 percent chance of survival without cancer recurrence, whereas those who received Z-BEAM were shown to have a 64 percent chance of survival, a significant improvement for lymphoma patients. Prognosis varied widely depending on the circumstances of disease and patient age, but those who did not have limiting factors and received Z-BEAM were shown to have a 100 percent chance of survival at two-year follow-up.

"The major significance of this study is in its encouraging overall survival rateresults improved to survival of more than two years in increasing numbers of patients, giving them a better chance overall with very low side effects with Z-BEAM compared to BEAM alone, which appeared to be rather inferior in its results during this study," said Zwas, who also mentioned that further studies are required to expand this regimen into general clinical practice.

Approximately 79,030 people are expected to be diagnosed with lymphoma in 2013. Lymphoma-associated deaths are estimated at 20,200 this year, according to the National Cancer Institute.


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Novel Liver Stem Cell Model Could Speed Up Process for Developing New Drugs
2. RSNA: ‘Heading’ a Soccer Ball Could Lead to Brain Injury
3. Heading a soccer ball could lead to brain injury
4. Reducing Unnecessary and High-dose Pediatric CT Scans Could Cut Associated Cancers by 62 Percent
5. Woman Who Let Powerball Winner Cut in Line Could Still Live Life of Affordable Luxury with a New Bathroom Remodel
6. New Report: Using Pharmacy Networks in Medicaid Could Save New York an Additional $3.7 Billion
7. School-located vaccination programs could reduce flu cases and deaths among children
8. Bladder cancer recurrence and mortality could decline with better treatment compliance
9. Neighborhood features could prevent obesity
10. Technique could identify patients at high risk of stroke or brain hemorrhage
11. New method to test breast lesions could better detect cancer, save money by reducing repeat biopsies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
(Date:6/23/2016)... -- The National Pharmaceutical Council (NPC) today announced that ... organization as its newest member.  ... and chief scientific officer, Mallinckrodt Pharmaceuticals, will serve ... of Directors. ... in support of our efforts to conduct research ...
Breaking Medicine Technology: